Table 1.
Baseline participant demographic and assessment data (n = 36)
| Active (n = 19) | Placebo (n = 17) | p value | |||
|---|---|---|---|---|---|
| Mean | SD | Mean | SD | ||
| Age (years) | 76.31 | 8.79 | 73.88 | 6.97 | 0.369 |
| Gender (male/female) | 15 (78.9%)/4 (21.1%) | 12 (70.6%)/5 (29.4%) | 0.563 | ||
| DLB/PDD | 12 (63.2%)/7 (36.8%) | 11 (64.7%)/6 (35.3%) | 0.923 | ||
| Levodopa equivalent dose (mg) | 225.63 | 318.79 | 186.73 | 264.87 | 0.695 |
| Cognitive fluctuations, n (%) | 18 (94.7%) | 17 (100%) | 0.337 | ||
| Parkinsonism, n (%) | 14 (73.7%) | 14 (82.4%) | 0.532 | ||
| REM behaviour disorder, n (%) | 11 (52.4%) | 12 (63.2%) | 0.491 | ||
| MMSE | 18.16 | 6.56 | 17.88 | 6.06 | 0.897 |
| CAMCOG (total) | 60.05 | 22.91 | 58.24 | 21.39 | 0.808 |
| NPI hallucinations subscale | 4.42 | 2.80 | 4.47 | 3.16 | 0.961 |
| CAF | 6.32 | 3.92 | 5.65 | 2.55 | 0.553 |
| ODFAS | 4.58 | 3.39 | 4.71 | 2.97 | 0.906 |
| UPDRS-III | 36.83 | 25.07 | 32.36 | 21.93 | 0.561 |
| TMT A (% completion) | 52.2% | 47.8% | 0.923 | ||
| TMT B (% completion) | 5.3% | 5.9% | 0.935 | ||
| FAS | 17.26 | 14.75 | 14.94 | 11.21 | 0.602 |
| GDS-15 | 6.81 | 4.31 | 6.27 | 2.91 | 0.681 |
| IADL | 3.12 | 2.52 | 2.47 | 2.26 | 0.451 |
| CDR (total) | 1.24 | 0.71 | 1.29 | 0.56 | 0.790 |
SD standard deviation, DLB dementia with Lewy bodies, PDD Parkinson’s disease dementia, REM rapid eye movement, MMSE Mini-Mental State Examination, CAMCOG Cambridge Cognitive Examination, NPI Neuropsychiatric Inventory, CAF Cognitive Assessment of Fluctuation, ODFAS One Day Fluctuation Scale, UPDRS-III Unified Parkinson’s Disease Rating Scale, TMT Trail Making Test, GDS-15 Geriatric Depression Scale (15-item version), IADL Individual Activities of Daily Living; CDR Clinical Dementia Rating